Session R.A. II 4
4 · Taysha Gene Therapies, Inc. · Filed Feb 25, 2022
Insider Transaction Report
Form 4
Session R.A. II
DirectorPresident and CEO10% Owner
Transactions
- Award
Employee Stock Option (right to buy)
2022-02-23+217,850→ 217,850 totalExercise: $5.96Exp: 2032-02-23→ Common Stock (217,850 underlying)
Footnotes (1)
- [F1]25% of the total number of shares underlying the option shall vest and become exercisable on February 23, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.